Integration of in silico and in vitro platforms for pharmacokinetic–pharmacodynamic modeling

  title={Integration of in silico and in vitro platforms for pharmacokinetic–pharmacodynamic modeling},
  author={Jong Hwan Sung and Mandy B. Esch and Michael L. Shuler},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  pages={1063 - 1081}
Importance of the field: Pharmacokinetic–pharmacodynamic (PK-PD) modeling enables quantitative prediction of the dose–response relationship. Recent advances in microscale technology enabled researchers to create in vitro systems that mimic biological systems more closely. Combination of mathematical modeling and microscale technology offers the possibility of faster, cheaper and more accurate prediction of the drug's effect with a reduced need for animal or human subjects. Areas covered in this… 
Pharmacokinetic and pharmacodynamic insights from microfluidic intestine-on-a-chip models
Development of the intestinal wall, integration of the gut microbiome, and the provision of an intestine-specific environment must be achieved to realize in vivo-like intestinal model and enhance the efficiency of drug development.
Using physiologically-based pharmacokinetic-guided “body-on-a-chip” systems to predict mammalian response to drug and chemical exposure
Progress on systems for microscale models of mammalian systems that include two or more integrated cellular components that include physiologically-based pharmacokinetic (PBPK) modeling in the design are reviewed.
Multi-organ-on-a-chip for pharmacokinetics and toxicokinetic study of drugs
  • J. Sung
  • Biology, Chemistry
    Expert opinion on drug metabolism & toxicology
  • 2021
This work will review recent progress in the development of multi-organ-on-a-chip platforms for predicting PK and TK of drugs, as well as mathematical approaches that can be combined with these platforms for experiment design, data analysis and in vitro-in vivo extrapolation (IVIVE) for application to humans.
Pharmacokinetics-On-a-Chip: In Vitro Microphysiological Models for Emulating of Drugs ADME.
Synthesis of the ADME-centered organ-on-a-chip technology is systemically presented from what is achieved to what needs to be done, emphasizing the requirements of in vitro models that meet industrial needs in terms of the structure and functions.
Using PBPK guided “ Body-ona-Chip ” Systems to Predict Mammalian Response to Drug and Chemical Exposure
Progress on systems for microscale models of mammalian systems that include two or more integrated cellular components that include physiologically-based pharmacokinetic modeling and various approaches to measure responses are reviewed.
The role of body-on-a-chip devices in drug and toxicity studies.
Review efforts made toward the development of microfabricated cell culture systems and examples that demonstrate their potential use in drug development, such as identifying synergistic drug interactions as well as simulating multiorgan metabolic interactions.
Microtechnology‐based organ systems and whole‐body models for drug screening
The development of organ‐on‐a‐chip systems has progressed to include the reproduction of multiple organ interactions, which is an important step towards ”body‐on-a‐ chip“ systems that will ultimately predict whole‐body responses to drugs.
Preclinical in vivo ADME studies in drug development: a critical review
  • M. Pellegatti
  • Biology
    Expert opinion on drug metabolism & toxicology
  • 2012
The focus of this paper is on some ‘traditional' in vivo ADME studies: excretion balance, metabolic profile and WBA in the toxicological species and their value in the perspective of the contemporary drug development process.
In Vitro–In Silico Modeling of Caffeine and Diclofenac Permeation in Static and Fluidic Systems with a 16HBE Lung Cell Barrier
The developed in vitro–in silico modeling framework can be expanded further, integrating additional cell tissues in the fluidic system, and can be employed in future studies to model pharmacokinetic and pharmacodynamic drug behavior.


Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives
The purpose of this article is to review, from a historical perspective, the progression of the modelling of the concentration–response relationship from the first classic models developed in the mid-1960s to some of the more sophisticated current approaches.
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development
An update on the current state of PK/PD‐modeling from an academic, industrial and regulatory perspective is presented.
In vitro microscale systems for systematic drug toxicity study
It is envisioned that the ‘cells-on-a-chip’ technology will serve as a valuable link between in vitro and in vivo studies, reducing the demand for animal studies, and making clinical trials more effective.
Mechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects
It is shown that most of the published mathematical models can be derived from one common mechanism-based PK–PD model premised on cell growth and cell killing processes, and a new equation predicting the time to microorganisms eradication after repeated drug doses was derived.
Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
The results indicate that most of the simulated concentration-time profiles of plasma and 10 tissues are in reasonable agreement with the corresponding experimental data determined in vivo (less than a factor of two), however, some more relevant deviations were observed for specific tissues.
A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip.
Combination of a mathematical modeling approach (PK-PD modeling) and an in vitro experimental approach (microCCA) provides a novel platform with improved predictability for testing drug toxicity and can help researchers gain a better insight into the drug's mechanism of action.
Pharmacokinetic/pharmacodynamic studies in drug product development.
Rigorous implementation of the PK/PD concepts in drug product development provides a rationale, scientifically based framework for efficient decision making regarding the selection of potential drug candidates, for maximum information gain from the performed experiments and studies, and for conducting fewer, more focused clinical trials with improved efficiency and cost effectiveness.
Recent advances in pharmacokinetic modeling
  • A. Ahmad
  • Chemistry, Biology
    Biopharmaceutics & drug disposition
  • 2007
This review highlights a variety of recent advances in mechanistic pharmacokinetic modeling and the roles of statistical applications and population methodologies are discussed where appropriate.